Preoperative analysis of 11q loss using circulating tumor-released DNA in serum: A novel diagnostic tool for therapy stratification of neuroblastoma

Cancer Letters

Volumn 309, Issue 2, 2011, Pages 185-189

  Yagyu, Shigeki ^a   Iehara, Tomoko ^a   Gotoh, Takahiro ^a   Miyachi, Mitsuru ^a   Katsumi, Yoshiki ^a   Kikuchi, Ken ^a   Tsuchiya, Kunihiko ^a   Osone, Shinya ^a,b   Kuroda, Hiroshi ^a,b   Sugimoto, Tohru ^a,c   Sawada, Tadashi ^a   Hosoi, Hajime ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO CITY HOSPITAL   (Japan)

^c Medical Care Center   (Japan)

Author keywords

11q; LOH; Microsatellite analysis; Neuroblastoma; Serum DNA

Indexed keywords

DNA; DNA FRAGMENT;

ALLELE; ARTICLE; BLOOD ANALYSIS; CANCER MORTALITY; CANCER SURVIVAL; CHILD; CHROMOSOME 11Q; CHROMOSOME DELETION; CHROMOSOME LOSS; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; INFANT; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NEUROBLASTOMA; PREDICTION; PREOPERATIVE EVALUATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS;

ALLELES; BASE SEQUENCE; CHILD, PRESCHOOL; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; DNA; DNA FRAGMENTATION; HUMANS; INFANT; MICROSATELLITE REPEATS; NEUROBLASTOMA; PROGNOSIS; SEQUENCE DELETION;

EID: 79960840747     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.05.032     Document Type: Article

References (33)

1. Brodeur G.M., Maris J.M. Neuroblastoma. Principles and Practice of Pediatric Oncology, fourth ed. 2002, Lippincott Williams and Wilkins, Philadelphia. P.A. Pizzo, D.G. Poplack (Eds.).
2. Brodeur G.M., Seeger R.C., Schwab M., et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984, 224:1121-1124.
3. Seeger R.C., Brodeur G.M., Sather H., et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. New Engl. J. Med. 1985, 313:1111-1116.
4. Ohira M., Oba S., Nakamura Y., et al. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 2005, 7:337-350.
5. Wei J.S., Greer B.T., Westermann F., et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res. 2004, 64:6883-6891.
6. Oberthuer A., Berthold F., Warnat P., et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J. Clin. Oncol. 2006, 24:5070-5078.
7. Banelli B., Gelvi I., Di Vinci A., et al. Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors. Oncogene 2005, 24:5619-5628.
8. van Noesel M.M., van Bezouw S., Voute P.A., et al. Clustering of hypermethylated genes in neuroblastoma. Genes Chromosomes Cancer 2003, 38:226-233.
9. Yang Q., Kiernan C.M., Tian Y., et al. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin. Cancer Res. 2007, 13:3191-3197.
10. Misawa A., Inoue J., Sugino Y., et al. Methylation-associated silencing of the nuclear receptor 1I2 gene in advanced-type neuroblastomas, identified by bacterial artificial chromosome array-based methylated CpG island amplification. Cancer Res. 2005, 65:10233-10242.
11. Abe M., Ohira M., Kaneda A., et al. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res. 2005, 65:828-834.
12. Attiyeh E.F., London W.B., Mosse Y.P., et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. New Engl. J. Med. 2005, 353:2243-2253.
13. Maris J.M., Guo C., Blake D., et al. Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Med. Pediatr. Oncol. 2001, 36:32-36.
14. Janoueix-Lerosey I., Schleiermacher G., Michels E., et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J. Clin. Oncol. 2009, 27:1026-1033.
15. Guo C., White P.S., Weiss M.J., et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 1999, 18:4948-4957.
16. Guo C., White P.S., Hogarty M.D., et al. Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas. Med. Pediatr. Oncol. 2000, 35:544-546.
17. Luttikhuis M.E., Powell J.E., Rees S.A., et al. Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis. Br. J. Cancer 2001, 85:531-537.
18. Cohn S.L., Pearson A.D., London W.B., et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report. J. Clin. Oncol. 2009, 27:289-297.
19. Hero B., Simon T., Spitz R., et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J. Clin. Oncol. 2008, 26:1504-1510.
20. De Bernardi B., Gerrard M., Boni L., et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J. Clin. Oncol. 2009, 27:1034-1040.
21. Gotoh T., Hosoi H., Iehara T., et al. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction. J. Clin. Oncol. 2005, 23:5205-5210.
22. Yagyu S., Gotoh T., Iehara T., et al. Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma. Clin. Cancer Res. 2008, 14:7011-7019.
23. Brodeur G.M., Pritchard J., Berthold F., et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol. 1993, 11:1466-1477.
24. Sellner L.N., Taylor G.R. MLPA and MAPH: new techniques for detection of gene deletions. Hum. Mutat. 2004, 23:413-419.
25. Ambros I.M., Brunner B., Aigner G., et al. A multilocus technique for risk evaluation of patients with neuroblastoma. Clin. Cancer Res. 2011, 17:792-804.
26. Goebel G., Zitt M., Zitt M., et al. Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. Dis. Mark. 2005, 21:105-120.
27. Shapiro B., Chakrabarty M., Cohn E.M., et al. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 1983, 51:2116-2120.
28. Leon S.A., Shapiro B., Sklaroff D.M., et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977, 37:646-650.
29. Nawroz H., Koch W., Anker P., et al. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat. Med. 1996, 2:1035-1037.
30. Sanchez-Cespedes M., Monzo M., Rosell R., et al. Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients. Ann. Oncol. 1998, 9:113-116.
31. Kolble K., Ullrich O.M., Pidde H., et al. Microsatellite alterations in serum DNA of patients with colorectal cancer. Lab Invest. 1999, 79:1145-1150.
32. Fujiwara Y., Chi D.D., Wang H., et al. Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. Cancer Res. 1999, 59:1567-1571.
33. Chen X., Bonnefoi H., Diebold-Berger S., et al. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin. Cancer Res. 1999, 5:2297-2303.